![Stephanie Tozzo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephanie Tozzo
Direttore Tecnico/Scientifico/R&S presso Avilar Therapeutics, Inc.
Patrimonio netto: - $ in data 30/06/2024
Profilo
Stephanie Tozzo currently works at Avilar Therapeutics, Inc., as Chief Science Officer & Senior Vice President from 2021.
Dr. Tozzo also formerly worked at CohBar, Inc., as Director from 2022 to 2023.
Dr. Tozzo received her graduate degree from Université Paris-Saclay.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
COHBAR INC
-.--% | 15/08/2023 | 0 ( -.--% ) | - $ | 30/06/2024 |
Posizioni attive di Stephanie Tozzo
Società | Posizione | Inizio |
---|---|---|
Avilar Therapeutics, Inc.
![]() Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Direttore Tecnico/Scientifico/R&S | 01/11/2021 |
Precedenti posizioni note di Stephanie Tozzo
Società | Posizione | Fine |
---|---|---|
COHBAR, INC. | Direttore/Membro del Consiglio | 10/11/2023 |
Formazione di Stephanie Tozzo
Université Paris-Saclay | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
COHBAR, INC. | Health Technology |
Aziende private | 1 |
---|---|
Avilar Therapeutics, Inc.
![]() Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
- Borsa valori
- Insiders
- Stephanie Tozzo